The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.

The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The present invention relates to newly identified sialyltransferases having alpha-2,3-sialyltransferase activity on the galactose residue of lactose. The invention also describes methods for the production of a 3sialylated oligosaccharide using any one of the newly identified sialyltransferases as well as the purification of the 3sialylated oligosaccharide. The present invention also provides a cell for production of the 3sialylated oligosaccharide and the use of the cell in a cultivation or incubation.

The present disclosure relates to enriched engineered glycoprotein populations with a therapeutically optimized heterogeneous glycan profile. The heterogeneous glycan profile comprises sialylated complex type glycans, which are associated with improved efficacy of the glycoprotein. The present disclosure also relates to compositions and uses of the engineered glycoprotein populations and cell-based method of producing them.

The present disclosure relates to enriched engineered glycoprotein populations with a therapeutically optimized heterogeneous glycan profile. The heterogeneous glycan profile comprises sialylated complex type glycans, which are associated with improved efficacy of the glycoprotein. The present disclosure also relates to compositions and uses of the engineered glycoprotein populations and cell-based method of producing them.

The present invention relates to a microorganism having an enhanced activity of a protein consisting of an amino acid sequence in which N-terminus 20 to 37 amino acid residues in the amino acid sequence represented by SEQ ID NO: 2 are deleted, where the microorganism has improved productivity of 3-sialyllactose as compared with that of a parent strain.